Assessment and management of resistant hypertension

CMAJ

Volumn 186, Issue 18, 2014, Pages E689-E697

  Padwal, Raj S ^a,b   Rabkin, Simon ^c   Khan, Nadia ^c,d  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d Center for Health Evaluation and Outcome Sciences   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMILORIDE; AMLODIPINE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CLONIDINE; DOXAZOSIN; EPLERENONE; FUROSEMIDE; HYDRALAZINE; HYDROCHLOROTHIAZIDE; IRBESARTAN; LABETALOL; METHYLDOPA; METOPROLOL; MINERALOCORTICOID ANTAGONIST; MINOXIDIL; NEBIVOLOL; RAMIPRIL; RENIN; SPIRONOLACTONE; TERAZOSIN; ANTIHYPERTENSIVE AGENT;

ADD ON THERAPY; AEROBIC EXERCISE; AORTA COARCTATION; CUSHING SYNDROME; DRUG TARGETING; ERECTILE DYSFUNCTION; GLOMERULONEPHRITIS; GYNECOMASTIA; HEALTH BEHAVIOR; HUMAN; HYPERCALCEMIA; HYPERTENSION; KIDNEY DENERVATION; KIDNEY DISEASE; LOW DRUG DOSE; PATIENT REFERRAL; PHEOCHROMOCYTOMA; PLASMA RENIN ACTIVITY; POSITIVE END EXPIRATORY PRESSURE; PREVALENCE; PRIMARY HYPERALDOSTERONISM; RENOVASCULAR DISEASE; RESISTANT HYPERTENSION; REVIEW; RISK FACTOR; SLEEP DISORDERED BREATHING; SODIUM RESTRICTION; THERAPY EFFECT; THYROID DISEASE; CASE REPORT; DRUG RESISTANCE; FEMALE; MIDDLE AGED;

ANTIHYPERTENSIVE AGENTS; DRUG RESISTANCE; FEMALE; HUMANS; HYPERTENSION; MIDDLE AGED;

EID: 84918775404     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.130764     Document Type: Review

References (65)

1. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008;51:1403-19.
2. Williams B. Resistant hypertension: an unmet treatment need. Lancet 2009;374:1396-8.
3. McAlister FA, Wilkins K, Joffres M, et al. Changes in the rates of awareness, treatment and control of hypertension in Canada over the past two decades. CMAJ 2011;183:1007-13.
4. Robitaille C, Dai S, Waters C, et al. Diagnosed hypertension in Canada: incidence, prevalence and associated mortality. CMAJ 2012;184:E49-56.
5. Gee ME, Bienek A, McAlister FA, et al. Factors associated with lack of awareness and uncontrolled high blood pressure among Canadian adults with hypertension. Can J Cardiol 2012;28:375-82.
6. McAdam-Marx C, Ye X, Sung JC, et al. Results of a retrospective, observational pilot study using electronic medical records to assess the prevalence and characteristics of patients with resistant hypertension in an ambulatory care setting. Clin Ther 2009;31:1116-23.
7. Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension 2011;57:1076-80.
8. Garg JP, Elliot WJ, Folker A, et al. Resistant hypertension revisited: a comparison of two university-based cohorts. Am J Hypertens 2005;18:619-26.
9. Yakovlevitch M, Black HR. Resistant hypertension in a tertiary care clinic. Arch Intern Med 1991;151:1786-92.
10. Pierdomenico SD, Lapenna D, Bucci A, et al. Cardiovascular outcome in treated hypertensive patients with responder, masked, false-resistant and true-resistant hypertension. Am J Hypertens 2005; 18:1422-8.
11. Dasgupta K, Quinn RR, Zarnke KB, et al. The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol 2014;30:485-501.
12. White LH, Bradley TD. Role of nocturnal rostral fluid shift in the pathogenesis of obstructive and central sleep apnea. J Physiol 2013;591:1179-93.
13. Rossi GP, Seccia TM, Maniero C, et al. Drug-related hypertension and resistance to antihypertensive treatment. J Hypertens 2011;29:2295-309.
14. Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2008;93:3266-81.
15. Trinquart L, Mounier-Vehier C, Sapoval M, et al. Efficacy of revascularization for renal artery stenosis caused by fibromuscular dysplasia: a systematic review and meta-analysis. Hypertension 2010;56:525-32.
16. Cooper CJ, Murphy TP, Cutlip DE, et al. Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med 2014; 370:13-22.
17. Raber W, Raffesberg W, Bischof M, et al. Diagnostic efficacy of unconjugated plasma metanephrines for the detection of pheochromocytoma. Arch Intern Med 2000;160:2957-63.
18. de la Sierra A, Segura J, Banegas JR, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 2011;57:898-902.
19. Pedrosa RP, Drager LF, Gonzaga CC, et al. Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension. Hypertension 2011;58:811-7.
20. Ruttanaumpawan P, Nopmaneejumruslers C, Logan AG, et al. Association between refractory hypertension and obstructive sleep apnea. J Hypertens 2009;27:1439-45.
21. Rossi GP. Prevalence and diagnosis of primary aldosteronism. Curr Hypertens Rep 2010;12:342-8.
22. Rossi GP, Bernini G, Caliumi C. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006;48:2293-300.
23. Calhoun DA. Obstructive sleep apnea and hypertension. Curr Hypertens Rep 2010;12:189-95.
24. Sica DA. What is the role of aldosterone excess in resistant hypertension and how should it be investigated and treated? Curr Cardiol Rep 2011;13:520-6.
25. Korner PI. Essential hypertension and its causes. Neural and non-neural mechanisms. New York: Oxford University Press; 2007.
26. Katholi RE, Rocha-Singh KJ. The role of renal sympathetic nerves in hypertension: Has percutaneous renal denervation refocused attention on their clinical significance? Prog Cardiovasc Dis 2009;52:243-8.
27. Fisher JP, Paton JF. The sympathetic nervous system and blood pressure in humans: implications for hypertension. J Hum Hypertens 2012;26:463-75.
28. Laragh J. Laragh's lessons in pathophysiology and clinical pearls for treating hypertension. Am J Hypertens 2001;14:491-503.
29. Hu LJ, Chen YQ, Deng SB, et al. Additional use of an aldosterone antagonist in patients with mild to moderate chronic heart failure: a systematic review and meta-analysis. Br J Clin Pharmacol 2013;75:1202-12.
30. Wu HY, Huang JW, Lin HJ, et al. Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis. BMJ 2013;347:f6008.
31. Lv J, Perkovic V, Foote CV, et al. Antihypertensive agents for preventing diabetic kidney disease. Cochrane Database Syst Rev 2012;12:CD004136.
32. Maione A, Navaneethan SD, Graziano G, et al. Angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials. Nephrol Dial Transplant 2011; 26: 2827-47.
33. Al-Mallah MH, Tleyjeh IM, Abdel-Latif AA, et al. Angiotensin-converting enzyme inhibitors in coronary artery disease and preserved left ventricular systolic function: a systematic review and meta-analysis of randomized controlled trials. J Am Coll Cardiol 2006;47:1576-83.
34. Yusuf S, Teo KK, Poque J, et al; ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59.
35. Freemantle N, Cleland J, Young P, et al. Beta-blockade after myocardial infarction: systematic review and meta-regression analysis. BMJ 1999;318:1730-7.
36. Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 2000;355:1575-81.
37. Verdecchia P, Angeli F, Cavallini C, et al. Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis. Eur Heart J 2009; 30: 679-88.
38. Foody JM, Farrell MH, Krumholz HM. Beta-blocker therapy in heart failure: scientific review. JAMA 2002;287:883-9.
39. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41.
40. Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367:2204-13.
41. Dimeo F, Pagonas N, Seibert F, et al. Aerobic exercise reduces blood pressure in resistant hypertension. Hypertension 2012; 60:653-8.
42. Hermida RC, Ayala DE, Calvo C, et al. Effects of time of day of treatment on ambulatory blood pressure pattern of patients with resistant hypertension. Hypertension 2005;46:1053-9.
43. Hermida RC, Ayala DE, Mojón A, et al. Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study. Chronobiol Int 2010;27:1629-51.
44. Padwal R. Applying the 2005 Canadian Hypertension Education Program recommendations: 3. Lifestyle modifications to prevent and treat hypertension. CMAJ 2005;173:749-51.
45. Pimenta E, Gaddam KK, Oparil S, et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension 2009; 54:475-81.
46. Lozano L, Tovar JL, Sampol G, et al. Continuous positive airway pressure treatment in sleep apnea patients with resistant hypertension: a randomized, controlled trial. J Hypertens 2010;28:2161-8.
47. Egan BM, Basile JN, Rehman SU, et al. Plasma renin test-guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trial. Am J Hypertens 2009;22:792-801.
48. Olson N, DeJongh B, Hough A, et al. Plasma renin activity-guided strategy for the management of hypertension. Pharmacotherapy 2012;32:446-55.
49. Preston RA, Materson BJ, Reda DJ. Age-race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. JAMA 1998;280:1168-72.
50. Turner ST, Schwartz GL, Chapman AB, et al. Plasma renin activity predicts blood pressure responses to beta-blocker and thaizide diuretic as monotherapy and add-on therapy for hypertension. Am J Hypertens 2010;23:1014-22.
51. Handler J. Overlapping spironolactone dosing in primary aldosteronism and resistant essential hypertension. J Clin Hypertens (Greenwich) 2012;14:732-4.
52. Eide IK, Torjesen PA, Drolsum A, et al. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens 2004;22:2217-26.
53. Goodfriend TL. Treating resistant hypertension with a neglected old drug. Hypertension 2007;49:763-4.
54. Václavik J, Sedlák R, Plachy M, et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension 2011;57:1069-75.
55. Bobrie G, Frank M, Azizi M, et al. Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension. J Hypertens 2012;30:1656-64.
56. Esunge PM. From blood pressure to hypertension: the history of research. J R Soc Med 1991;84:621.
57. Esler MD, Krum H, Sobotka PA, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010;376:1903-9.
58. Persu A, Renkin J, Thijs L, et al. Renal denervation ultima ratio or standard in treatment-resistant hypertension. Hypertension 2012; 60:596-606.
59. Mahfoud F, Schlach M, Kindermann I, et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation 2011; 123: 1940-6.
60. Hering D, Lambert EA, Marusic P, et al. Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertension. Hypertension 2013;61: 457-64.
61. Brandt MC, Mahfoud F, Reda S, et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol 2012;59:901-9.
62. Khan NA, Herman RJ, Quinn RR, et al. Renal denervation therapy for the treatment of resistant hypertension: a position statement by the Canadian Hypertension Education Program. Can J Cardiol 2014; 30:16-21.
63. Bhatt DL, Kandzari DE, O'Neill WW, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014; 370:1393-401.
64. Messerli FH, Bangalore S. Renal denervation for resistant hypertension? N Engl J Med 2014;370:1454-7.
65. Laurent S, Schlaich M, Esler M. New drugs, procedures, and devices for hypertension. Lancet 2012;380:591-600.